ArticleMaterials today. Bio2025
Multifunctional Prussian lue nanozymes ameliorate tendinopathy via modulating tissue homeostasis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in ultrasound-mediated nanozyme systems in therapeutic applications.Ultrasonics sonochemistry · 2026Review
- The Role of Phagocytic Cells in the Achilles Tendon.International journal of molecular sciences · 2026Review
- Biomimetic "Tendon Band-Aid" regulates inflammatory microenvironment and tenogenic differentiation for tendinopathy regeneration.Journal of nanobiotechnology · 2026Article
- Prussian Blue Nanoparticles Promoting Diabetic Bone Regeneration via Mitochondrial Recovery.BME frontiers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tendinopathy, a prevalent musculoskeletal disorder characterized by chronic pain and functional decline, remains a therapeutic challenge due to the limited efficacy of conventional treatments in addressing oxidative stress and persistent inflammation. Here, we present Prussian blue nanozymes (PBzymes) as a catalytic nanomedicine engineered to mimic multi-enzyme activities, offering a potent strategy for tendon microenvironment modulation and repair. Synthesized via a hydrothermal template-free approach, PBzymes exhibit robust reactive oxygen species (ROS)-scavenging capabilities through intrinsic superoxide dismutase, catalase, and peroxidase-like activities, effectively neutralizing •OH, H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.